No open-market selling at Fibrogen Inc in the past year, which is unusual. Instead one officers and board members bought into about $34,000 worth of FGEN.
The largest purchase came from Wettig Thane (CEO), about $25,000. C-suite participation is part of the picture here.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 3 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 17, 2025 | Wettig Thane | CEO | Buy | 1,000 | $9.18 | $9K | SEC |
| Nov 17, 2025 | Wettig Thane | CEO | Buy | 2,700 | $9.10 | $25K | SEC |
| Jul 2, 2025 | Schoeneck James A | Director | Buy | 23,567 | $5.07 | $119K | SEC |
| Mar 25, 2025 | Wettig Thane | CEO | Buy | 145,000 | $0.35 | $51K | SEC |
| Mar 24, 2025 | Schoeneck James A | Director | Buy | 250,000 | $0.35 | $88K | SEC |
| Mar 24, 2025 | Schoeneck James A | Director | Buy | 50,000 | $0.34 | $17K | SEC |
| Jun 13, 2024 | Adib Deyaa | Executive Officer | Buy | 22,123 | $1.17 | $26K | SEC |
| Mar 11, 2024 | Wettig Thane | CEO | Buy | 50,000 | $1.91 | $96K | SEC |
| Sep 6, 2023 | Henderson Jeffrey William | Director | Sell | 2,000 | $1.03 | $2K | SEC |
| Aug 8, 2023 | Henderson Jeffrey William | Director | Sell | 2,000 | $1.91 | $4K | SEC |
| Jul 13, 2023 | Henderson Jeffrey William | Director | Sell | 2,000 | $2.69 | $5K | SEC |
| Jul 10, 2023 | Conterno Enrique A | CEO | Sell | 1,880 | $2.80 | $5K | SEC |
| Jun 26, 2023 | Wettig Thane | Executive Officer | Sell | 791 | $16.53 | $13K | SEC |
| Jun 22, 2023 | Wettig Thane | Executive Officer | Sell | 472 | $17.04 | $8K | SEC |
| Jun 22, 2023 | Wettig Thane | Executive Officer | Sell | 1,286 | $17.04 | $22K | SEC |
In the last 12 months Fibrogen Inc insiders made open-market purchases worth about $34,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in FGEN was filed on 2025-11-17.
No congressional trades in FGEN were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).